Results 151 to 160 of about 5,427 (186)

Perforated primary adenocarcinoma of the colon with choriocarcinoma differentiation treated with targeted colorectal cancer chemotherapy: a case report. [PDF]

AME Case Rep
Ishimaru N, Tagami T, Yamasaki M, Niwa K.   +3 more
europepmc   +1 more source

LSD1 inhibition attenuates targeted therapy-induced lineage plasticity in BRAF mutant colorectal cancer. [PDF]

Mol Cancer
Ladaika CA, Chakraborty A, Masood A, Hostetter G, Yi JM, O'Hagan HM.   +5 more
europepmc   +1 more source

A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancer. [PDF]

Int J Clin Oncol
Ando T, Oya Y, Tomiie Y, Ogawa K, Kuki T, Tanabe Y, Kato H, Imaizumi K, Hibi Y, Kawada K.   +9 more
europepmc   +1 more source

Severe symptomatic cardiac dysfunction in a patient with BRAF V600E-mutated metastatic colorectal cancer treated with encorafenib, binimetinib, and cetuximab: a case report. [PDF]

J Pharm Health Care Sci
Kondo M, Nagao Y, Hayashi S, Wakita E, Noda M, Okada I, Wachino C, Yamada-Nishide K, Hori M, Hotta Y, Matsuo Y, Furukawa-Hibi Y.   +11 more
europepmc   +1 more source

Transoral videolaryngoscopic surgery for hypopharyngeal anaplastic metastasis from papillary thyroid carcinoma. [PDF]

JCEM Case Rep
Yokoyama Y, Nishio N, Sugiura M, Suzuki K, Wada A, Sone M.   +5 more
europepmc   +1 more source

Post-marketing surveillance of encorafenib in combination with binimetinib in Japanese patients with BRAF-mutant melanoma. [PDF]

Int J Clin Oncol
Yamazaki N, Sakata H, Iida O, Katayama T, Uhara H.   +4 more
europepmc   +1 more source

Treatment-Related Adverse Events in Individuals with BRAF-Mutant Cutaneous Melanoma Treated with BRAF and MEK Inhibitors: A Systematic Review and Meta-Analysis. [PDF]

Cancers (Basel)
Belloni S, Virgili R, Caruso R, Arrigoni C, Magon A, Rocco G, De Maria M.   +6 more
europepmc   +1 more source

Inhibitors of De Novo Guanylate Biosynthesis Enhance the Potency of MAPK Cascade Inhibitors Against Colorectal Cancer. [PDF]

Int J Mol Sci
Maslov AA, Trageser NH, Kichina JV, Elamir H, Gardner E, Teaman F, Vishwanath V, Dugas SM, Bianchi-Smiraglia A, Leonova KI, Gurova KV, Nikiforov MA, Kandel ES.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Encorafenib and Binimetinib

2021
The BRAF/MEK inhibitors, encorafenib and binimetinib, is the FDA/EMA-approved combination used in BRAF-positive melanoma. The phase III study showed an improvement in progression-free survival (PFS) and overall survival (OS) with good tolerability. A direct comparison of monotherapy showed better results in the arm with encorafenib over vemurafenib ...
Iwona Lugowska, Paweł Rogala
openaire   +1 more source